Illumina, Next Generation Genomic to launch VeriSeq™ NIPT Solution in Thailand

KUALA LUMPUR, June 2 -- Illumina Inc and Next Generation Genomic Co Ltd (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, have announced the launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to non-invasive prenatal testing (NIPT).

Illumina Vice President and General Manager of Asia Pacific and Japan, Gretchen Weightman, explained the availability of VeriSeq NIPT Solution v2 was a key milestone in the partnership between Illumina and NGG Thailand.

“Illumina’s comprehensive technologies, coupled with NGG Thailand’s expertise, will enable healthcare providers and expectant parents to unlock the most critical information possible today,” said Weightman. The automated in-lab IVD solution will allow NGG Thailand to launch the Qualifi Prenatal Test and be the first laboratory in South East Asia to detect anomalies that targeted assays miss and deliver more insights into the health of a pregnancy compared to standard NIPT offerings.

Illumina, the global leader in DNA sequencing and array-based technologies in a statement said, using its VeriSeq NIPT Solution v2, the test delivers a comprehensive view of the fetal genome compared to other CE-IVD NIPT products.

This enables healthcare providers to support expectant parents with informed, timely and personalised pregnancy management options better than ever before.

NGG Thailand’s Qualifi Prenatal Test uses VeriSeq NIPT Solution v2 to provide accurate information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw.

The CE-IVD VeriSeq NIPT Solution v2 is now registered for use in Thailand, Vietnam, Singapore, South Korea, Australia, New Zealand, South Africa and across most countries in Europe.

More details at www.illumina.com.

-- BERNAMA